MLYS

+ Watchlist + Portfolio

Mineralys Therapeutics, Inc.

Regulated industry Physical products Development stageTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $23.72
52-Week Range: $22.30 – $47.65
Market Cap: $2.08B
P/E (TTM): —
EPS (TTM): -4.22
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 3.79
PEG Ratio: —
Return on Equity: -80.88%
Return on Assets: -46.18%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 34.46
Debt/Equity: 0.18
Total Debt: $97.62M
Free Cash Flow: $-203.46M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $1.53B

MLYS Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$0.00	$0.00
Research & Development	$26.25M	$70.36M	$168.58M	$132.01M
Selling, General & Admin	$5.23M	$14.30M	$23.82M	$38.59M
Operating Expenses	$31.48M	$84.66M	$192.40M	$170.60M
Operating Income	-$31.48M	-$84.66M	-$192.40M	-$170.60M
EBITDA	-$31.48M	-$84.66M	-$192.36M	-$170.54M
Pretax Income	-$29.80M	-$71.90M	-$177.81M	-$154.65M
Net Income	-$29.80M	-$71.90M	-$177.81M	-$154.65M
Diluted EPS	-0.76	-1.99	-3.66	-2.29
Diluted Shares	39.06M	36.19M	48.54M	67.66M

MLYS Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$87.70M	$49.30M	$114.09M	$172.92M
Current Assets	$112.81M	$249.10M	$205.35M	$661.39M
Total Assets	$114.44M	$251.64M	$205.90M	$661.81M
Current Liabilities	$8.07M	$10.48M	$14.65M	$15.11M
Total Liabilities	$166.71M	$10.48M	$14.65M	$15.11M
Retained Earnings	-$52.81M	-$124.71M	-$302.52M	-$457.17M
Shareholders' Equity	-$52.27M	$241.15M	$191.26M	$646.69M
Working Capital	$104.74M	$238.62M	$190.71M	$646.27M

MLYS Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$29.22M	-$81.17M	-$166.31M	-$142.42M
Capital Expenditure	—	—	-$96.00K	-$15.00K
Free Cash Flow	-$29.22M	-$81.17M	-$166.41M	-$142.43M
Depreciation & Amortisation	—	$0.00	$43.00K	$59.00K
Stock-Based Compensation	$455.00K	$5.06M	$11.34M	$19.32M
Investing Cash Flow	-$21.76M	-$160.47M	$114.96M	-$389.75M
Financing Cash Flow	$128.02M	$203.25M	$116.14M	$591.00M
Share Repurchases	-$1.63M	—	—	—
Net Change in Cash	$77.04M	-$38.40M	$64.79M	$58.83M

MLYS Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	$37.88M	$38.28M	$31.45M	$24.40M	$24.36M	$221.38M
Selling, General & Admin	$6.57M	$8.47M	$9.68M	$13.88M	$20.98M	$24.66M
Operating Expenses	$44.45M	$46.75M	$41.13M	$38.28M	$45.34M	$246.04M
Operating Income	-$44.45M	-$46.75M	-$41.13M	-$38.28M	-$45.34M	-$246.04M
EBITDA	-$44.43M	-$46.73M	-$41.12M	-$38.27M	-$45.33M	-$246.03M
Pretax Income	-$42.21M	-$43.27M	-$36.93M	-$32.23M	-$39.34M	-$241.07M
Net Income	-$42.21M	-$43.27M	-$36.93M	-$32.23M	-$39.34M	-$241.07M
Diluted EPS	-0.79	-0.66	-0.52	-0.40	-0.47	-2.85
Diluted Shares	53.16M	65.45M	70.59M	80.55M	82.83M	84.73M

MLYS Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$165.01M	$101.79M	$217.60M	$172.92M	$112.78M	$138.27M
Current Assets	$354.51M	$335.27M	$599.80M	$661.39M	$652.47M	$665.80M
Total Assets	$354.94M	$335.72M	$599.95M	$661.81M	$652.86M	$667.85M
Current Liabilities	$13.39M	$22.17M	$23.52M	$15.11M	$14.72M	$19.32M
Total Liabilities	$13.39M	$22.17M	$23.52M	$15.11M	$14.72M	$116.94M
Retained Earnings	-$344.73M	-$388.00M	-$424.94M	-$457.17M	-$496.51M	-$737.58M
Shareholders' Equity	$341.56M	$313.55M	$576.43M	$646.69M	$638.14M	$550.92M
Working Capital	$341.12M	$313.10M	$576.28M	$646.27M	$637.75M	$646.48M

MLYS Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$45.49M	-$30.17M	-$28.87M	-$37.89M	-$39.47M	-$32.56M
Free Cash Flow	-$45.49M	-$30.17M	-$28.87M	-$37.90M	-$39.47M	-$32.56M
Depreciation & Amortisation	$15.00K	$16.00K	$15.00K	$13.00K	$6.00K	$5.00K
Stock-Based Compensation	$3.65M	$4.55M	$5.84M	$5.29M	$6.55M	$7.36M
Investing Cash Flow	-$92.88M	-$42.88M	-$150.51M	-$103.49M	-$44.94M	-$185.22M
Financing Cash Flow	$189.28M	$9.83M	$295.19M	$96.70M	$24.27M	$243.26M
Net Change in Cash	$50.92M	-$63.22M	$115.81M	-$44.68M	-$60.14M	$25.49M

Market Snapshot

About

Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for hypertension and chronic kidney disease. The company's lead candidate, lorundrostat, is an aldosterone synthase inhibitor designed to lower blood pressure and reduce cardiovascular and renal risk. Mineralys targets patients with uncontrolled hypertension and cardiorenal conditions.